SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Celsius Holdings, Inc. engages in the development, marketing, sale, and distribution of functional drinks and liquid supplements. It also offers post-workout functional energy drinks and protein bars. The company was founded in April 2004 and is headquartered in Boca Raton, FL.

Celsius Holdings Inc

Celsius Holdings is trending as investors focus on an upcoming earnings report, with the community actively debating whether the company can maintain its rapid growth despite concerns over increased competition from store-brand alternatives and broader margin pressures. While some investors express frustration over recent price volatility and potential institutional manipulation, others remain bullish on the long-term potential of the PepsiCo distribution partnership and the successful integration of Alani Nu.

Gorilla Technology Group, Inc. engages in the provision of video intelligence, Internet of Things (IoT) security, edge AI data analytics, and operational technology security solutions and services in Asia Pacific. It operates through the following segments: Video IoT, Security Convergence, and Other. The company was founded by Spincer Koh in May 2001 and is headquartered in London, the United Kingdom.

Gorilla Technology Group Inc

Gorilla Technology Group is currently trending as investors react to a significant data center campus development in Thailand and an expanded partnership with Yotta, fueling speculation about long-term revenue potential and a possible short squeeze due to high short interest and a limited tradable float. The community is actively debating the legitimacy of these massive contract announcements and the company's ability to finance them, with many longs expressing high conviction in the stock's future as it attempts to break through key technical resistance levels.

Fastly, Inc. provides real-time content delivery network services. It offers edge compute, edge delivery, edge security, edge applications like load balancing and image optimization, video on demand, and managed edge delivery. The company was founded by Artur Bergman, Tyler McMullen, Simon Wistow, and Gil Penchina in March 2011 and is headquartered in San Francisco, CA.

Fastly Inc - Ordinary Shares - Class A

Fastly Inc

Fastly is experiencing extreme volatility and a sharp sell-off as investors re-evaluate the stock following its rapid appreciation and news regarding the competitive landscape for edge AI agents. The community is deeply divided, with many traders debating whether this is a structural failure or a temporary overreaction offering a bargain buy-the-dip opportunity for the long term.

AppLovin Corp. engages in the development and operation of a mobile marketing platform. It offers AppDiscovery, MAX, Adjust, and SparkLabs. Its software-based platform caters to mobile application developers to improve the marketing and monetization of applications. The company was founded by Andrew Karam, John Krystynak, and Adam Foroughi in 2011 and is headquartered in Palo Alto, CA.

Applovin Corp - Ordinary Shares - Class A

Applovin Corp

AppLovin is generating significant buzz as traders closely watch its upcoming earnings report, with the community split between betting on a massive breakout driven by AI-powered ad revenue and fears of volatility and manipulation. The stock remains a polarizing focal point as investors debate whether current software sector headwinds or the company's strong fundamentals and buyback activity will dictate the next major price move.

Aurinia Pharmaceuticals, Inc. is a clinical stage bio-pharmaceutical company, which engages in the research, development, and commercialization of therapeutic drugs. The company was founded by Robert Foster, Richard Glickman, and Michael Martin on June 16, 1993 and is headquartered in Edmonton, Canada.

Aurinia Pharmaceuticals Inc

Aurinia Pharmaceuticals is trending as investors react to a significant leadership overhaul that replaced the former CEO with Chairman Kevin Tang, sparking optimism for a potential buyout. The community is actively debating the strategic implications of Tangs aggressive management style and the company's recent acquisition of Kezar Life Sciences as key catalysts for future value creation.

Snap, Inc. is a technology company, which engages in the provision of a visual messaging application that was created to help people communicate through short videos and images. The company was founded by Frank Reginald Brown IV, Evan Thomas Spiegel, and Robert C. Murphy in 2010 and is headquartered in Santa Monica, CA.

Snap Inc - Ordinary Shares - Class A

Snap Inc

Snap Inc. is trending as investors react to a quarterly report that beat estimates for revenue and free cash flow but triggered concerns over North American user growth and conservative guidance. The community is sharply divided between those betting on a long-term turnaround fueled by cost-cutting and potential AI integration, and others venting frustration over stagnant share performance and perceived leadership failures.

Himax Technologies, Inc. is a semiconductor solution provider dedicated to display imaging processing technologies. It operates through the Driver Integrated Circuit and Non-Driver Products segments. The company's products include display drivers, timing controllers, wafer level optics, video and display technology solutions, liquid crystal over silicon silicon, complementary metal-oxide semiconductor image sensor, and power integrated circuit. Its products used in TVs, laptops, monitors, mobile phones, tablets, digital cameras, car navigation, virtual reality (VR) devices and many other consumer electronics devices. Himax Technologies was founded by Biing Seng Wu and Jordan Wu on June 12, 2001 and is headquartered in Tainan, Taiwan.

Himax Technologies - ADR

Himax Technologies, Inc.

Himax Technologies is currently trending following a report identifying the company as a key stealth supplier for Nvidia and Apple's advanced optical infrastructure, specifically regarding wafer-level optics for Co-Packaged Optics. The community is actively debating the sustainability of this price action, with some investors pointing to long-term growth in AI data center components, while skeptics caution against potential volatility and speculative hype.

Xanadu Quantum Technologies Ltd. engages in the provision of quantum computing solutions for enterprise and government customers. The company was founded by Christian Weedbrook on October 2, 2025 and is headquartered in Toronto, Canada.

Xanadu Quantum Technologies Ltd. - Ordinary Shares - Class B (Sub Voting)

Xanadu Quantum Technologies is experiencing significant volatility as market participants react to a resale registration filing that increases the number of shares available for trading. While some investors are concerned about potential supply overhang and the company's early-stage financials, the community is actively debating whether this sell-off is an overreaction or a structural reset for the quantum infrastructure play.

Pagaya Technologies Ltd. engages in the development of AI and data networks for the financial industry. Its product deploys data science, machine learning and AI technology to evaluate the customers' applications in real time. The company was founded by Gal Krubiner, Sanjiv Das, Yahav Yulzari, and Avital Pardo on March 20, 2016 and is headquartered in New York, NY.

Pagaya Technologies Ltd - Ordinary Shares - Class A

Pagaya Technologies Ltd

Pagaya Technologies is seeing significant investor attention driven by a combination of strong institutional backing through recent AAA-rated bond deals and anticipation surrounding their upcoming first-quarter earnings report. While the community is actively debating the stock's valuation versus its underlying AI-driven credit underwriting model, many long-term holders remain focused on the company's sustained GAAP profitability and a growing network of financial partners.

Amprius Technologies, Inc. engages in the development, manufacture, and market of lithium-ion batteries for mobility applications, including the aviation, electric vehicle and light electric vehicle industries. It operates through the following geographical segments: North America, EMEA, and Asia Pacific. The company was founded by Mark C. Platshon in 2008 and headquartered in Fremont, CA.

Amprius Technologies Inc

Amprius Technologies is trending due to the company securing a $21 million purchase order for its SiCore cylindrical batteries from a major new electric mobility customer in China. Investors are closely monitoring the stock's price action as it attempts to maintain a sustained trading range above $18, which is a critical threshold for triggering the forced exercise of outstanding public warrants.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

<ul class="summary-bullets"><li>Atara is jointly developing the drug with Pierre Fabre Pharmaceuticals.</li><li>The FDA stated that a single-arm study using a historical control group could support a future marketing application.</li><li>FDA had rejected an initial application submitted by Atara in January 2026, raising concerns about the trial design and analysis.</li></ul>Shares of Atara Biotherapeutics (ATRA) surged more than 43% in morning trade on Thursday, recording their biggest single-day gains in more than two years, after the biotech firm announced a promising update from the U.S. Food and Drug Administration (FDA) tied to its experimental blood cancer therapy.<a href="https://stocktwits.com/symbol/ATRA">ATRA shares</a> also breached the 100-day moving average (100-DMA) for the first time in nearly four months.<a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.tradingview.com/chart/teA7VKVN/?symbol=NASDAQ%3AATRA"><img src="https://news.stocktwits-cdn.com/ATRA_jpg_7fc3a2b23b.webp" alt="ATRA.jpg"></a>Source: TradingView<h2 class="st-heading-2">FDA Talks Signal Resubmission Hopes For ATRA’s Immunotherapy</h2>Atara said it made progress with the FDA on a potential path to resubmitting the biologics license application (BLA) for Tabelecleucel. The drug is used for the treatment of Epstein-Barr virus-associated post-transplant lymphoproliferative disease (EBV+ PTLD).The update followed a recent Type A meeting between the FDA, Atara, and its partner, Pierre Fabre Pharmaceuticals, after the agency issued a Complete Response Letter (CRL) earlier this year, stating that it could not approve the application in its current form.However, the FDA has now stated that a single-arm study using a historical control group could support a future marketing application. Pierre Fabre plans to include updated results from its Phase 3 study, including additional patient data and longer follow-up, as part of the resubmission package.Atara and Pierre Fabre are jointly developing the drug.<h2 class="st-heading-2">Why Did FDA Reject ATRA’s Initial Application?</h2>The FDA <a href="https://stocktwits.com/news-articles/markets/equity/atra-rises-on-pushing-for-meeting-with-fda-on-rare-disease-drug-rejection/cZdeli8RIP1">previously</a> declined to approve Tabelecleucel, stating the company’s study did not provide enough evidence for accelerated approval and raised concerns about the trial design and analysis.Pierre Fabre responded to the agency, providing additional explanations and arguing that the study was properly controlled and suitable to support the application. The company also submitted updated long-term efficacy data, along with supportive development and European post-marketing data, for a potential resubmission.<h2 class="st-heading-2">Retail Skeptical About ATRA’s Rally</h2>Retail sentiment on Stocktwits turned ‘extremely bullish’ from ‘neutral’ a day earlier, amid ‘extremely high’ message volumes.However, one user stated the news did not justify the rally.<stembedurl>https://stocktwits.com/robanbieber/message/652581236</stembedurl>Another user called ATRA’s chart setup “neutral” and saw support between $6.50 and $7.<stembedurl>https://stocktwits.com/independentresearch1/message/652578353</stembedurl>ATRA shares have been under heavy selling pressure this year, slumping nearly 60%.Read also: <a href="https://stocktwits.com/news-articles/markets/equity/ibrx-bulls-shrug-off-earnings-loss-retail-traders-eye-a-crucial-fda-deadline/cZXbg96ReQT">IBRX Bulls Shrug Off Earnings Loss -- Retail Traders Eye A Crucial FDA Deadline</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

ATRA Stock Sees Biggest Single-Day Gain In Over 2 Years, Breaches Key Technical Milestone – New FDA Update Has Bulls Circling Back

 Atara said it made progress with the FDA on a potential path to resubmitting the biologics license application for its immunotherapy Tabelecleucel.

Equity

Atara said it made progress with the FDA on a potential path to resubmitting the biologics license application for its immunotherapy Tabelecleucel.

Healthcare Disruption, AI Biologics, and Wall Street Upgrades Ignite a Midday Market Surge

Healthcare innovators are pushing the markets today. $TGNT, $AGL, $ATRA, $ASBP

Atara Biotherapeutics Provides Regulatory Update on Tabelecleucel

Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop transformative therapies for patients...

Atara Biotherapeutics, Inc. (ATRA) Shareholders Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit

Atara Biotherapeutics, Inc. (ATRA) Shareholders Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit Atara Biotherapeutics, Inc. (ATRA) Shareholders Who Lost Money Have Opportunity to...

The Gross Law Firm Reminds Atara Biotherapeutics, Inc. Investors of the Pending Class Action Lawsuit With a Lead Plaintiff Deadline of May 22, 2026 - ATRA

The Gross Law Firm Reminds Atara Biotherapeutics, Inc. Investors of the Pending Class Action Lawsuit With a Lead Plaintiff Deadline of May 22, 2026 - ATRA The Gross Law Firm Reminds Atara...

ATRA Investors Have Opportunity to Lead Atara Biotherapeutics, Inc. Securities Fraud Lawsuit

ATRA Investors Have Opportunity to Lead Atara Biotherapeutics, Inc. Securities Fraud Lawsuit ATRA Investors Have Opportunity to Lead Atara Biotherapeutics, Inc. Securities Fraud Lawsuit PR Newswire...

ATRA SHAREHOLDER REMINDER: Faruqi & Faruqi, LLP Reminds Atara Biotherapeutics (ATRA) Investors of Securities Class Action Deadline on May 22, 2026

ATRA SHAREHOLDER REMINDER: Faruqi & Faruqi, LLP Reminds Atara Biotherapeutics (ATRA) Investors of Securities Class Action Deadline on May 22, 2026 ATRA SHAREHOLDER REMINDER: Faruqi & Faruqi, LLP...

Pomerantz Law Firm Announces the Filing of a Class Action Against Atara Biotherapeutics, Inc. and Certain Officers - ATRA

Pomerantz Law Firm Announces the Filing of a Class Action Against Atara Biotherapeutics, Inc. and Certain Officers - ATRA Pomerantz Law Firm Announces the Filing of a Class Action Against Atara...

Lost Money on Atara Biotherapeutics, Inc.(ATRA)? Join Class Action Suit Seeking Recovery - Contact Levi & Korsinsky

Lost Money on Atara Biotherapeutics, Inc.(ATRA)? Join Class Action Suit Seeking Recovery - Contact Levi & Korsinsky Lost Money on Atara Biotherapeutics, Inc.(ATRA)? Join Class Action Suit Seeking Recovery - Contact Levi & Korsinsky PR Newswire NEW YORK, April 29, 2026 NEW YORK, April 29, 2026...

The Gross Law Firm Reminds Shareholders of a Lead Plaintiff Deadline of May 22, 2026 in Atara Biotherapeutics, Inc. Lawsuit - ATRA

The Gross Law Firm Reminds Shareholders of a Lead Plaintiff Deadline of May 22, 2026 in Atara Biotherapeutics, Inc. Lawsuit - ATRA The Gross Law Firm Reminds Shareholders of a Lead Plaintiff Deadline...

Atara Biotherapeutics, Inc. is an allogeneic T-cell immunotherapy company, which engages in the development of transformative therapies for patients with serious diseases including solid tumors, hematologic cancers, and autoimmune diseases. It also delivers off-the-shelf treatments to patients with high unmet medical need. Its product pipeline includes Tab-cel, ATA188, ATA2271/ATA3271, and ATA3219. The company was founded by Isaac E. Ciechanover on August 22, 2012 and is headquartered in Thousand Oaks, CA.

Atara Biotherapeutics Inc

Still early innings

Overdone

Consolidation due before next leg up

Memory stocks have surged over the past year - is the run overdone or still early innings?

Stocktwits

Stocktwits Polls

Traders are reacting to a regulatory update from an FDA Type A meeting, which provides a clearer path for the resubmission of tabelecleucel.

Aggressive retail buying and high volatility are putting immense pressure on short positions, leading to calls for a potential parabolic move.

Market participants are fixated on key technical breakouts above $8.60 and critical support zones at $7.00 to map out entries and exits.

Current Price	$7.84
Prev Close	$5.15
Open	$7.86
Dividend Yield	0.00%
50-Day Moving Average	$5.15
Beta	2.24
Avg. Volume	64,042.83
PE Ratio	1.77

52-Week High	$19.15
52-Week Low	$3.92
Market Capitalization	$43.84M
EPS (Annual)	$2.57
Price to Book	-0.98
Revenue Per Employee	$8.63M

ATRA
Atara Biotherapeutics Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest ATRA News

ATRAAtara Biotherapeutics Inc